Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on September 2, 2020, reporting events occurring on September 1, 2020. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol REXN.
Key Financial Metrics
This filing is a current report regarding a specific corporate transaction and does not contain periodic financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material event reported is the entry into a Warrant Exchange Agreement with Anson Investments Master Fund LP. Under this agreement:
- The Company issued an aggregate of 192,878 shares of Common Stock to Anson.
- In exchange, Anson surrendered and cancelled four existing warrant tranches (2016, 2017, 2018, and 2019 Warrants).
- The cancelled warrants covered a total of 412,451 shares (62,500 + 44,192 + 160,257 + 145,502) on a post-reverse stock split basis.
Guidance, Outlook, and Risks
The filing does not contain management guidance, future outlook, or specific risk factors beyond the standard disclosure that the issuance of shares was made in reliance on Section 3(a)(9) of the Securities Act of 1933. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the exact terms of the Warrant Exchange Agreement filed as Exhibit 10.1.
- Confirm the impact of the 192,878 new share issuance on total outstanding shares and potential dilution.
- Review the historical context of the cancelled warrants (2016-2019) to understand the original strike prices and expiration dates that were extinguished.
- Check subsequent filings for any changes in the company's capital structure or cash position resulting from this transaction.